A001630 Stock Overview
Manufactures and distributes pharmaceutical products in South Korea and internationally. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 1/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
Chong Kun Dang Holdings Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩51,300.00 |
52 Week High | ₩64,300.00 |
52 Week Low | ₩47,150.00 |
Beta | 0.57 |
11 Month Change | -7.57% |
3 Month Change | -6.73% |
1 Year Change | -8.06% |
33 Year Change | -31.69% |
5 Year Change | -45.31% |
Change since IPO | 67.20% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By Chong Kun Dang Holdings Corp.'s (KRX:001630) Low P/E
Nov 14Benign Growth For Chong Kun Dang Holdings Corp. (KRX:001630) Underpins Its Share Price
Aug 06We Think That There Are Some Issues For Chong Kun Dang Holdings (KRX:001630) Beyond Its Promising Earnings
Mar 27Recent updates
Why Investors Shouldn't Be Surprised By Chong Kun Dang Holdings Corp.'s (KRX:001630) Low P/E
Nov 14Benign Growth For Chong Kun Dang Holdings Corp. (KRX:001630) Underpins Its Share Price
Aug 06We Think That There Are Some Issues For Chong Kun Dang Holdings (KRX:001630) Beyond Its Promising Earnings
Mar 27Here's Why Chong Kun Dang Holdings (KRX:001630) Has A Meaningful Debt Burden
Apr 28Could Chong Kun Dang Holdings Corp. (KRX:001630) Have The Makings Of Another Dividend Aristocrat?
Apr 08Here's Why I Think Chong Kun Dang Holdings (KRX:001630) Is An Interesting Stock
Mar 01The Chong Kun Dang Holdings (KRX:001630) Share Price Has Gained 54% And Shareholders Are Hoping For More
Feb 14Is Weakness In Chong Kun Dang Holdings Corp. (KRX:001630) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Feb 01Chong Kun Dang Holdings (KRX:001630) Has A Pretty Healthy Balance Sheet
Jan 19Should Chong Kun Dang Holdings Corp. (KRX:001630) Be Part Of Your Dividend Portfolio?
Jan 06Do Institutions Own Chong Kun Dang Holdings Corp. (KRX:001630) Shares?
Dec 24Chong Kun Dang Holdings's (KRX:001630) Earnings Are Growing But Is There More To The Story?
Dec 11Here's Why I Think Chong Kun Dang Holdings (KRX:001630) Might Deserve Your Attention Today
Nov 28Shareholder Returns
A001630 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | 1.0% | -3.1% | 2.9% |
1Y | -8.1% | 4.8% | -2.8% |
Return vs Industry: A001630 underperformed the KR Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: A001630 underperformed the KR Market which returned -2.8% over the past year.
Price Volatility
A001630 volatility | |
---|---|
A001630 Average Weekly Movement | 4.0% |
Pharmaceuticals Industry Average Movement | 5.2% |
Market Average Movement | 5.6% |
10% most volatile stocks in KR Market | 11.6% |
10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A001630 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A001630's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1941 | 37 | n/a | www.ckd-holdings.com/company/summary.do |
Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally. The company was founded in 1941 and is based in Seoul, South Korea.
Chong Kun Dang Holdings Corp. Fundamentals Summary
A001630 fundamental statistics | |
---|---|
Market cap | ₩244.22b |
Earnings (TTM) | ₩48.13b |
Revenue (TTM) | ₩946.09b |
5.1x
P/E Ratio0.3x
P/S RatioIs A001630 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A001630 income statement (TTM) | |
---|---|
Revenue | ₩946.09b |
Cost of Revenue | ₩521.72b |
Gross Profit | ₩424.37b |
Other Expenses | ₩376.24b |
Earnings | ₩48.13b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 10.11k |
Gross Margin | 44.86% |
Net Profit Margin | 5.09% |
Debt/Equity Ratio | 55.7% |
How did A001630 perform over the long term?
See historical performance and comparison